NASDAQ$GHRS
GH Research PLC · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
GH Research Q2 2025: $9.3M net loss as Phase 2b TRD data shows 73% remission, cash $308.7M
GH Research PLC reported Q2 2025 results for the quarter ended June 30, 2025, with a net loss of $9.3 million ($0.15 loss per share) compared to a $10.4 million loss ($0.20 per share) in Q2 2024. Research and development expenses were $9.0 million, down from $9.8 million, while general and administrative expenses rose to $5.7 million from $3.5 million on higher professional fees. Cash, cash equivalents and marketable securities totaled $308.7 million versus $182.6 million at year-end 2024, bolstered by a $150 million Q1 public offering. The company reported full Phase 2b TRD data showing 73% remission at 6 months with infrequent treatment visits, ongoing FDA engagement on its GH001 IND, and plans to initiate a global pivotal program in 2026.
- Net loss $9.3M ($0.15/share) vs $10.4M loss ($0.20/share) in Q2 2024
- R&D expenses $9.0M (-8% YoY); G&A $5.7M (+63% YoY); cash position $308.7M
- Phase 2b TRD trial met primary endpoint with 73% remission at 6 months in open-label extension
- GH001 IND complete response ongoing with FDA; one hold topic remaining
- Global pivotal program initiation on track for 2026; GH002 IND submission expected Q4 2025
Headline financials
Revenue & EPS history
GH Research · Revenue · Quarterly
$0
Forward guidance
Global pivotal program for GH001 in treatment-resistant depression expected to initiate in 2026; GH002 IND submission planned Q4 2025
Tailwinds
- Phase 2b TRD primary endpoint met with highly significant MADRS reduction
- Strong cash runway from $150M Q1 offering supports pivotal program preparation
Headwinds
- GH001 IND still subject to one remaining FDA hold topic
- Pre-revenue stage with ongoing clinical development costs
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2025
+0.7%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+0.3%
Avg return
30 days after
55%
6 / 11 earnings
Positive
+24.4%
Q3 2021
Best reaction
-19.3%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | +0.2% | -3.7% | |
| Q3 2025 | -1.2% | +4.6% | +9.6% | |
| Q4 2025 | -4.8% | -10.2% | -21.6% | |
| Q2 2025 | +2.2% | +10.2% | +19.3% | |
| Q4 2024 | -2.9% | -14.4% | +0.8% | |
| Q2 2024 | -19.3% | -21.6% | -37.8% | |
| Q1 2024 | +4.5% | +7.1% | +25.9% | |
| Q2 2023 | -5.8% | +1.2% | -5.0% | |
| Q1 2023 | +8.2% | +6.9% | +24.6% | |
| Q4 2021 | +1.1% | +7.5% | -15.6% | |
| Q3 2021 | +24.4% | +24.4% | +7.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro